Surgery is often the first step in the treatment of cancer patients. However, even when the surgery successfully removes the tumor, the risk of cancer recurrence still exists. Traditional imaging and histological tests can only detect significant changes when the tumor has grown or metastasized, making it impossible to capture the tiny remnants of cancer cells in time. This means that many patients may appear to be cancer-free after surgery, but potential cancer cells remain, leading to disease recurrence.

The Concept of Circulating Tumor Cell (CTC) Micro Residue

Circulating Tumor Cells (CTCs) are cancer cells that detach from the primary tumor and enter the bloodstream. These cells can exist in very low concentrations in the blood, undetectable by imaging tests, yet still lead to distant metastasis or recurrence. Research has shown that the presence of CTCs is closely related to the risk of cancer recurrence and metastasis and serves as an important marker for detecting micro-residue of the disease.

After surgery, a small number of cancer cells (i.e., micro-residue) may circulate through the bloodstream. Even though the patient seems to recover, these small cancer cells may grow in other parts of the body and trigger a recurrence. Therefore, early detection of these micro-residual cancer cells is critical to improving treatment success rates and survival.

RGCC Detection: Precisely Identifying Micro Residue CTCs

RGCC’s CTC detection technology is one of the most advanced liquid biopsy methods available today, efficiently extracting and analyzing CTCs from blood samples. This method can detect micro-residual cancer cells in cancer patients after surgery, even in the absence of obvious clinical symptoms. By regularly monitoring CTCs, doctors can predict the risk of cancer recurrence early and adjust the patient’s follow-up care plan accordingly.

Advantages of RGCC CTC Detection:

1. Non-invasive: Only a blood sample is required, eliminating the need for surgery or other invasive procedures, greatly reducing the patient’s burden.
2. High Sensitivity: Capable of detecting minute amounts of tumor cells in the blood, effectively identifying micro-residual cancer cells.
3. Real-time Feedback: CTC testing provides real-time data, allowing doctors to make precise adjustments to the treatment plan based on the patient’s current condition.
4. Predicting Cancer Recurrence: Regular CTC monitoring helps detect the presence of cancer cells early, preventing recurrence and improving patient prognosis.

CTC Detection and Personalized Care

Based on the results of RGCC’s CTC detection, doctors can design personalized care plans for patients, intervening early to address micro-residual cancer cells. This could include strengthening immune system support, using adjunctive therapies (such as targeted drugs or immunotherapy), and enhancing nutrition and lifestyle adjustments. This comprehensive approach not only improves treatment outcomes but also reduces the risk of recurrence after surgery.

Post-surgery Monitoring and Treatment Adjustment

Regular CTC testing helps detect micro-residual cancer cells after surgery, providing more accurate post-operative monitoring. Doctors can adjust the follow-up care plan based on the results, ensuring that patients remain in the best possible health.

For example, if CTC testing reveals the presence of micro cancer cells, the doctor may choose additional care strategies, such as intensifying chemotherapy, using targeted therapies, or immunotherapy, to prevent the micro-residual cancer cells from recurring or metastasizing.

Conclusion

Micro-residual cancer cells after surgery are often the root cause of cancer recurrence, and these tiny cells may remain undetected by imaging tests. RGCC’s CTC detection provides a revolutionary method for early detection and monitoring of cancer recurrence. By identifying and eliminating these hidden cancer cells, it helps patients maintain long-term health after surgery. This highly sensitive liquid biopsy technology will become an essential tool in post-surgery cancer management, aiding doctors in developing more accurate and personalized care plans.

References

1. Pantel, K., & Alix-Panabières, C. (2010). Circulating tumor cells in cancer patients: Challenges and perspectives. Trends in Molecular Medicine, 16(9), 478-485. https://doi.org/10.1016/j.molmed.2010.07.001
2. Nagrath, S., Sequist, L. V., Maheswaran, S., et al. (2007). Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature, 450(7173), 1235-1239. https://doi.org/10.1038/nature06385
3. Cristofanilli, M., Budd, G. T., Ellis, M. J., et al. (2004). Circulating tumor cells, disease progression, and survival in metastatic breast cancer. The New England Journal of Medicine, 351(8), 781-791. https://doi.org/10.1056/NEJMoa041993
4. Williams, J. A., & Manikandan, M. (2016). Role of nutrition in cancer therapy. Integrative Cancer Therapies, 15(3), 391-402. https://doi.org/10.1177/1534735415619072
5. Azzini, G., & Salvi, A. (2008). The role of nutrition in cancer prevention and treatment. Journal of Clinical Oncology, 26(7), 1332-1336. https://doi.org/10.1200/JCO.2007.15.5072

Medical Disclaimer:

The information provided in this article is for educational and reference purposes only and does not constitute medical advice nor should it be used as a substitute for professional medical diagnosis, treatment, or advice. ALWAYS CONSULT ANY QUESTIONS YOU MAY HAVE ABOUT YOUR MEDICAL CONDITION OR MEDICAL PROBLEM ALWAYS CONSULT YOUR PHYSICIAN OR OTHER QUALIFIED HEALTH PROFESSIONAL. The content of this article is not intended to recommend any specific test, treatment, or medication and should not be construed as such. If you develop symptoms or require medical assistance, please contact a healthcare professional promptly.